 |
PDBsum entry 3vj9
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.5.1.21
- squalene synthase.
|
|
 |
 |
 |
 |
 |

Pathway:
|
 |
Squalene and Phytoene Biosynthesis
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
2 (2E,6E)-farnesyl diphosphate + NADPH + H+ = squalene + 2 diphosphate + NADP+
|
|
2.
|
2 (2E,6E)-farnesyl diphosphate + NADH + H+ = squalene + 2 diphosphate + NAD+
|
|
 |
 |
 |
 |
 |
2
×
(2E,6E)-farnesyl diphosphate
|
+
|
NADPH
|
+
|
H(+)
|
=
|
squalene
|
+
|
2
×
diphosphate
|
+
|
NADP(+)
|
|
 |
 |
 |
 |
 |
2
×
(2E,6E)-farnesyl diphosphate
|
+
|
NADH
|
+
|
H(+)
|
=
|
squalene
|
+
|
2
×
diphosphate
|
+
|
NAD(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Mn(2+) or Mg(2+)
|
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Biol Chem
287:18750-18757
(2012)
|
|
PubMed id:
|
|
|
|
|
| |
|
Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase.
|
|
C.I.Liu,
W.Y.Jeng,
W.J.Chang,
T.P.Ko,
A.H.Wang.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Zaragozic acids (ZAs) belong to a family of fungal metabolites with nanomolar
inhibitory activity toward squalene synthase (SQS). The enzyme catalyzes the
committed step of sterol synthesis and has attracted attention as a potential
target for antilipogenic and antiinfective therapies. Here, we have determined
the structure of ZA-A complexed with human SQS. ZA-A binding induces a local
conformational change in the substrate binding site, and its C-6 acyl group also
extends over to the cofactor binding cavity. In addition, ZA-A effectively
inhibits a homologous bacterial enzyme, dehydrosqualene synthase (CrtM), which
synthesizes the precursor of staphyloxanthin in Staphylococcus aureus to cope
with oxidative stress. Size reduction at Tyr(248) in CrtM further increases the
ZA-A binding affinity, and it reveals a similar overall inhibitor binding mode
to that of human SQS/ZA-A except for the C-6 acyl group. These structures pave
the way for further improving selectivity and development of a new generation of
anticholesterolemic and antimicrobial inhibitors.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |